2018CSCO临床指南：持续／复发及转移性分化型甲状腺癌的诊断和治疗（英文版）.PDF

  Guidelines Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer 2018 (English version) Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer working group doi: 10.21147/j.issn.1000-9604.2019.01.06 View this article at: /10.21147/j.issn.1000-9604.2019.01.06 Contents of specialists with complementary expertise (endocrinology, surgery, nuclear medicine, radiology, pathology, oncology, 1. Diagnosis and dynamic assessment of persistent/recurrent and molecular diagnostics, and epidemiology) should be      metastatic differentiated thyroid cancer (prmDTC) included in the MDT management of prmDTC. The 1.1 Basic principles of diagnosis diagnosis or further managements of prmDTC which may 1.2 Diagnostic methods include surgical managment, radioiodine-131 (131I) therapy, 1.3 Ongoing assessment of response to therapy thyroid stimulating hormone (TSH) suppressive therapy, as 2. Multidisciplinary treatment of prmDTC well as molecular targeted therapy (or being enrolled in 2.1 Basic principles of treatment certain clinical trial) or radiation therapy, etc., should be 2.2 Surgical management tailored according to comprehensive consideration of       2.2.1 Preoperative clinical assessment MDT.       2.2.2 Principles of surgical treatment for prmDTC 2.3 131I therapy